Senior Director, National and Strategic Accounts

Senior Director, National and Strategic Accounts

Remote

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It’s an exciting time to be part of Team Olema , with our transfor mation into a fully integrated oncology company well underway , t op-line data from our lead program expected later this year , and our first potential commercial launch on the horizon.

Our lead product candidate,palazestrant, isa novel, orallyavailablecomplete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently intwopivotal

Phase 3clinicaltrials.

We expect top-line data from OPERA-01,our ongoing

Phase 3 trial ofpalazestrantas a monotherapy in patients with second- or third-lineER+/HER2-metastatic breast cancer (MBC), in the fallwhich, if successful, could lead to our first potential approval and commercial launchin 2027. OPERA-02,our Phase 3 trial ofpalazestrantin combination withribociblibin patients with frontlineER+/HER2- MBC, is enrolling patients.

Togetherwith its mechanism of action, pharmacokinetic properties,andthe potential todemonstrateactivity in bothESR1wild-type and mutant tumors,palazestranthas the potential to transform the metastatic breast cancer treatment paradigm andaccessa $15 billion global market opportunity.

Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor withthepotential to generate further value and meaningfullyimpactthemetastatic breastcancertreatment landscape – particularly in combination withpalazestrant.

We recently reported encouraging

Phase 1monotherapydata from this program across multiple solid tumor types andareadvancingpatientenrollment in theongoingcombinationarmsin MBC.

Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires aresolute approach to developing better therapies and apassionateteamdedicated tohelping the patients we serve feel better,longer.

Wepossessadeepcommitment toour shared purpose,the sustained pursuit of excellence, cultivatingthecouragerequiredto advance our programs, drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. Team Olema is made up of nimble self-starters who bring consistency in their quest for the extraordinary every single day.

Ifyou’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together– for our patients, for your career, and for what’s beyond .

The Senior Director , National and Strategic Accounts will be a key member of the Market Access leadership team and will be responsible for the development of the Market Access Payer strategic plan and vision for business opportunities in various national and regional markets to support the launch of first product, palazestrant, along with future indications and additional therapies. Reporting to the Vice President of Market Access, the Senior Director will be both a strategic and tactical expert in the areas of Market access, payer coverage, and contracting and possess an intimate knowledge of the business of oncology and of the makeup of the provider accounts and networks.

You will work as a functional leader, a strategic thinker, and a team member with the ability to execute a national and regional market access strategy that creates patient access. This individual analyzes the market in terms of coverage and reimbursement, existing and emerging payer policies, formulary listings, competitive landscape, trends, pricing, contracting strategies, potential barriers to provider and patient access.

This leader informs…